pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1h ago·1 min read
save

Expert warns that newer obesity GLP-1 drugs could spark access battles in low-income nations

Nov 16, 2026·read at STAT ↗Negative

Lower‑cost generic versions of semaglutide, sold as Wegovy for obesity, have begun appearing in several markets and are expected to reach more countries soon. At the same time, pharmaceutical companies are racing to create next‑generation GLP‑1 medicines that promise greater efficacy, fewer side effects, and easier administration.

Ken Shadlen, a professor at the London School of Economics who studies pharmaceutical policy, cautions that these newer obesity treatments may become the next major arena for disputes over drug access in low‑income nations. He argues that without proactive measures, the gap between high‑priced innovative drugs and the ability of poorer countries to obtain them could widen.

Shadlen suggests drugmakers should develop licensing strategies now to ensure broader availability if the newer agents reach the market. Preparing such plans early could help mitigate future conflicts over pricing and distribution, and support global efforts to address obesity.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Expert warns of battleground over global access to newer GLP-1 drugs for obesity”

read at STAT ↗
548 words · retrieved 8m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 44m agoSTAT+: In a win for MAHA, FDA creates new regulatory category for the supplement NACSTAT
  • 1h agoSTAT+: NIAID acting head John Powers III appointed as the permanent directorSTAT
  • 2h agoSTAT+: Biotech’s rebound isn’t lifting all boats equallySTAT
  • 2h agoSTAT+: Suing Joe the Plumber and Microsoft, and diminishing raisesSTAT
  • 5h agoSTAT+: Pharmalittle: We’re reading about GLP-1 use, Covid-19 vaccine investment returns, and moreSTAT